Mallinckrodt Pharmaceuticals
Following a July 31, 2025 corporate combination and subsequent separation, two independent companies operate from the same legacy: one focused on specialty therapeutics for rare or underserved conditions across multiple clinical areas, and the other focused on development and large-scale manufacture of generics, sterile injectables, and APIs supported by a U.S.-based manufacturing network.
Industries
N/A
Nr. of Employees
medium (51-250)
Patents
Apparatus and method for detecting liquid level in a clear or partially clear container
US-12491330-B2
View DetailsSystems and methods for manufacturing and safety of an NO2-to-NO reactor cartridge used to deliver no for inhalation therapy to a patient
US-12257391-B2
View Details
Apparatus and method for detecting liquid level in a clear or partially clear container
US-12491330-B2
View DetailsSystems and methods for manufacturing and safety of an NO2-to-NO reactor cartridge used to deliver no for inhalation therapy to a patient
US-12257391-B2
View DetailsServices
Development of specialty therapeutics focused on rare, stigmatized, or unaddressed conditions across immunology, urology, hepatology, ophthalmology, orthopedics, and critical care.
End-to-end development and commercial manufacturing of generic medicines, sterile injectables, and active pharmaceutical ingredients supported by a U.S.-advantaged manufacturing network.
Development of specialty therapeutics focused on rare, stigmatized, or unaddressed conditions across immunology, urology, hepatology, ophthalmology, orthopedics, and critical care.
End-to-end development and commercial manufacturing of generic medicines, sterile injectables, and active pharmaceutical ingredients supported by a U.S.-advantaged manufacturing network.
Expertise Areas
- Specialty therapeutics development
- Generic pharmaceuticals
- Sterile injectable manufacturing
- API manufacturing
Key Technologies
- Generic drug formulation
- Aseptic/sterile manufacturing and fill-finish
- API synthesis and scale-up
- Commercial pharmaceutical manufacturing network
News & Updates
On July 31, 2025 the companies combined; the generics and sterile injectables business was later spun off as an independent company and the specialty therapeutics business was rebranded in November 2025.
On July 31, 2025 the companies combined; the generics and sterile injectables business was later spun off as an independent company and the specialty therapeutics business was rebranded in November 2025.